Pulmatrix Inc

NASDAQ PULM

Data sourced from iex and EODHD
Download Data

Pulmatrix Inc Earnings Per Share (EPS), Diluted 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 79.45%

Pulmatrix Inc Earnings Per Share (EPS), Diluted 1 year YoY Change (%) is 79.45% for the Trailing 12 Months (TTM) ending March 31, 2024, a 104.81% change year over year. Earnings Per Share (EPS), Diluted, is the portion of a company's profit allocated to each outstanding share of common stock, assuming the conversion of all potentially dilutive securities. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Pulmatrix Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -5.08, a 38.79% change year over year.
  • Pulmatrix Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -8.30, a 21.42% change year over year.
  • Pulmatrix Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -10.57, a 47.74% change year over year.
  • Pulmatrix Inc Earnings Per Share (EPS), Diluted for the Trailing 12 Months (TTM) ending March 31, 2020 was USD -20.22, a 74.60% change year over year.
NASDAQ: PULM

Pulmatrix Inc

CEO Mr. Teofilo David Raad MBA
IPO Date March 21, 2014
Location United States
Headquarters 99 Hayden Avenue, Lexington, MA, United States, 02421
Employees 22
Sector Healthcare
Industry Biotechnology
Description

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

StockViz Staff

September 19, 2024

Any question? Send us an email